Is it Too Late to Buy UnitedHealth Stock? | UNH Stock Analysis
Summary
Parkev analyzes UnitedHealth Group's recovery following a difficult 2025, where the company underestimated customer care costs and faced declining profitability. Parkev highlights that management's corrective actions in 2026 have led to better-than-expected results, causing the stock price to rise nearly 20% year-to-date. He emphasizes that Wall Street analysts have shifted from skepticism to optimism, with earnings-per-share growth estimates now aligned with management's long-term target of 13% to 16%.
Parkev notes that UnitedHealth Group has aggressively reduced its long-term debt by approximately $9 billion in 2026, bringing the total down to $71.4 billion. This 10% reduction is expected to lower interest expenses and enhance free cash flow, providing more room for share buybacks. Despite structural cost increases, Parkev believes the company's strategic exit from certain markets and adjusted pricing have stabilized the business.
Regarding valuation and price targets:
Mentioned Stocks
Reasoning: Parkev values the stock at $532 per share based on a Discounted Cash Flow model, while it currently trades at only $396. Parkev points out that management has successfully reduced debt by $9 billion and convinced Wall Street of their 13-16% long-term EPS growth potential. Even with a 20% YTD gain, Parkev believes the forward P/E of 17 makes it a compelling buy opportunity.